Tofacitinib-Induced Steroid-Free Remission in Subcutaneous Sarcoidosis With Neurologic Involvement: A Case Report

We report the case of a 62-year-old woman with subcutaneous sarcoidosis and probable neurologic involvement who achieved complete remission with tofacitinib without the use of systemic corticosteroids. The patient presented with multiple firm subcutaneous nodules on the extremities and limb weakness. Skin biopsy demonstrated non-caseating granulomas, and electromyography revealed neurogenic changes consistent with C5-C6 nerve root involvement. Treatment with tofacitinib 5 mg twice daily in combination with methotrexate 7.5 mg weekly led to complete resolution of both cutaneous lesions and neurologic symptoms within two months. Tofacitinib was discontinued after eight months, and remission was sustained at 11-month follow-up. This case illustrates the potential of JAK inhibition as an effective steroid-sparing therapeutic strategy in the management of multisystem sarcoidosis.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-09-04
DOI
https://doi.org/10.7759/cureus.91580
Primary Topic
Sarcoidosis and Beryllium Toxicity Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tofacitinib-Induced Steroid-Free Remission in Subcutaneous Sarcoidosis With Neurologic Involvement: A Case Report

Zhenrui Shi, Dan Hong, Jianchi Ma
Cureus
Sarcoidosis and Beryllium Toxicity Research
article

Tofacitinib-Induced Steroid-Free Remission in Subcutaneous Sarcoidosis With Neurologic Involvement: A Case Report

Zhenrui Shi, Dan Hong, Jianchi Ma
article en

Abstract

We report the case of a 62-year-old woman with subcutaneous sarcoidosis and probable neurologic involvement who achieved complete remission with tofacitinib without the use of systemic corticosteroids. The patient presented with multiple firm subcutaneous nodules on the extremities and limb weakness. Skin biopsy demonstrated non-caseating granulomas, and electromyography revealed neurogenic changes consistent with C5-C6 nerve root involvement. Treatment with tofacitinib 5 mg twice daily in combination with methotrexate 7.5 mg weekly led to complete resolution of both cutaneous lesions and neurologic symptoms within two months. Tofacitinib was discontinued after eight months, and remission was sustained at 11-month follow-up. This case illustrates the potential of JAK inhibition as an effective steroid-sparing therapeutic strategy in the management of multisystem sarcoidosis.

CureusVol. 17(9)
Sun Yat-sen University (CN), The Seventh Affiliated Hospital of Sun Yat-sen University (CN), Sun Yat-sen Memorial Hospital (CN)
Openalex Percentile: Top 70%
Sarcoidosis and Beryllium Toxicity Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Tofacitinib-Induced Steroid-Free Remission in Subcutaneous Sarcoidosis With Neurologic Involvement: A Case Report — Zhenrui Shi, Dan Hong, et al. · Cureus (2025) | TGRS Research Map | TGRS